Shanghai RAAS Blood Products News

Shanghai Rice (002252): Steady growth in performance empowers Haier Group

swhy researchOct 29, 2024 18:37

Shanghai Rice (002252) Depth: Haier takes the helm and leads the company to embark on a new journey

SWhy ResearchSep 22, 2024 13:11

Shanghai Rice (002252): Revenue growth exceeds expectations, profit is affected by one-off events

Aug 27, 2024 00:00

Shanghai Rice (002252): Haier Holdings has entered a new stage of development, and the expansion of pulp stations is worth looking forward to

Jul 10, 2024 00:00

Research reports | China Post Securities: Shanghai Raas Blood Products' equity transfer officially landed, and the company embarked on a new journey.

Gelonghui FinanceJun 20, 2024 15:55

Shanghai Rice (002252): Equity transfer officially landed at Haier to enable long-term development

Jun 19, 2024 00:00

Shanghai Rice (002252): Annual revenue is in line with expectations, investment losses affect profit

May 9, 2024 07:46

Shanghai Rice (002252): Annual revenue growth is in line with expectations

May 5, 2024 00:00

Shanghai Rice (002252): Performance continues to grow, pulping volume reaches a record high

Apr 30, 2024 00:00

Shanghai Laishi (002252) First Coverage Report: Major Shareholders Change Established Blood Products Companies to Revive New Vitality

Jan 22, 2024 00:00

Shanghai Rice (002252): Haier Group plans to become an actual controller, a new chapter is about to begin

Jan 5, 2024 11:32

Shanghai Rice (002252): Haier Group will become an actual controller to enable the company's medium- to long-term growth in all aspects

Jan 4, 2024 00:00

Shanghai Rice (002252): Haier Group's entry into the company ushered in a new chapter of development

Jan 1, 2024 00:00

Shanghai Rice (002252): Major shareholder change and implementation Haier Group is expected to empower the company's development

Dec 30, 2023 00:00

Shanghai Rice (002252): Haier Group plans to join the company to help the company develop in the long term

Dec 29, 2023 00:00

Research Report Nuggets: Dongwu Securities: First “buy” rating for Shanghai Laishi, on the cusp of industry integration

Gelonghui FinanceDec 4, 2023 16:24

Shanghai Laishi (002252): Proposed acquisition of Guangxi Guanfeng lays the foundation for future blood source expansion

Nov 11, 2023 00:00

Shanghai Rice (002252): Q3 revenue grew rapidly

Southwest SecuritiesOct 24, 2023 00:00

Shanghai Laishi (002252): Taking the lead in resuscitating Chunfeng blood products to reinvigorate

Southwest SecuritiesOct 20, 2023 00:00

Shanghai Rice (002252): Q2 is slightly lower in a single quarter and is still expected to maintain rapid growth throughout the year

銀河證券Aug 31, 2023 20:16